The FDA on Friday approved the use of icosapent ethyl as an adjunctive therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride levels, according to an agency press release.
Patients must also have either established CVD or diabetes and two or more additional risk factors for CVD.
Icosapent ethyl (Vascepa, Amarin) is the first FDA-approved drug to reduce CV risk among adults with elevated triglycerides as an add-on to maximally tolerated statin therapy.
The drug first netted approval in July 2012 for the reduction of triglycerides in adults with severe
Anupam Ghose, a physician by training, was diagnosed with Type 2 Diabetes Mellitus (T2DM) in 2017. After the diagnosis of T2DM, he followed a low carbohydrate high fat diet and reversed his T2DM within a year. Now he has one main goal in life and that is to make people understand that the conventional method of treating T2DM is not beneficial. Type 2 diabetes is reversible and the best way to reverse T2DM is through diet and lifestyle modifications. He now decided to help people with type 2 diabetes by offering online coaching to reverse their diabetes.